SPYRE THERAPEUTICS, INC. (SYRE) Total liabilities 2016–2025
SPYRE THERAPEUTICS, INC. (SYRE) total liabilities at each fiscal year-end, per SEC filings.
$62.5MFY2025 · since FY2016: $4.1M → $62.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $62.5M | -31.0% |
| FY2024 | $90.7M | +23.7% |
| FY2023 | $73.3M | +251.7% |
| FY2022 | $20.8M | -19.8% |
| FY2021 | $26.0M | +19.3% |
| FY2020 | $21.8M | -5.7% |
| FY2019 | $23.1M | +124.1% |
| FY2018 | $10.3M | +79.6% |
| FY2017 | $5.7M | +40.1% |
| FY2016 | $4.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More SYRE financial trends
SYRE RevenueSYRE Net incomeSYRE Net marginSYRE Gross profitSYRE Gross marginSYRE Operating incomeSYRE Operating marginSYRE Operating cash flowSYRE Free cash flowSYRE Capital expendituresSYRE Return on equitySYRE Stock buybacksSYRE Dividends paidSYRE Total assetsSYRE Shareholders’ equitySYRE overview →